The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Sweden

A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer

Phase 2 · randomised · 327 people · 86 sites in 7 countries · Running, not taking new patients

August 7, 2026
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Phase 3 · randomised · 450 people · 291 sites in 35 countries · Recruiting now

August 7, 2026
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Phase 3 · randomised · 700 people · 250 sites in 26 countries · Recruiting now

August 7, 2026
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Phase 3 · randomised · 1,000 people · 238 sites in 22 countries · Recruiting now

August 7, 2026